High-dose rifampicin and rifapentine in tuberculosis treatment Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015
Efficacy of intravenous isoniazid, rifampin and ethambutol administration in patients with failed treatment of tuberculosis and malabsorption syndrome Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Source: Eur Respir J 2001; 17: 641-646 Year: 2001
Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1526-1527 Year: 2016
Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine Source: Eur Respir J 2016; 48: 1527-1529 Year: 2016
Comparison of the Pharmacokinetics of a child-friendly Fixed-Dose Combination of rifampin and isoniazid and separate tablets in children with pulmonary tuberculosis. Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease Year: 2021
Evaluation of therapeutic response in isoniazid resistant TB Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006
Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Efficacy of anti-tuberculosis therapy with INH, RIF and Bedaquiline in mice with different genetic susceptibility to the infection Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Latent tuberculosis (infection). Evaluation of a short course treatment with isoniazid, rifampin and pyrazinamid Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
Efficacy and safety of levamisole as an immunomodulator in the treatment of drug resistant tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary? Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019 Year: 2019
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020